<SEC-DOCUMENT>0001144204-15-038204.txt : 20150622
<SEC-HEADER>0001144204-15-038204.hdr.sgml : 20150622
<ACCEPTANCE-DATETIME>20150622082749
ACCESSION NUMBER:		0001144204-15-038204
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150622
FILED AS OF DATE:		20150622
DATE AS OF CHANGE:		20150622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		15943742

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v413718_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: June 2015 (Report No.
2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>BIOBLAST PHARMA LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">37 Dereh Menechem Begin St., 15<SUP>th</SUP>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Tel Aviv 6522042 Israel</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Form 20-F &nbsp;<FONT STYLE="font-family: Wingdings">x
</FONT>Form 40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report of Foreign Private Issuer on
Form 6-K of the Registrant consists of the press release issued by the Registrant on June 22, 2015, announcing preclinical proof-of-concept
results of its read-through platform in Spinal Muscular Atrophy, which is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The first through fourth paragraphs of the
press release attached to this Form 6-K of the Registrant are incorporated by reference into the registration statement on Form
S-8 (File No. 333-203114) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date
on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release issued by BioBlast Pharma Ltd. on June 22, 2015, announcing preclinical proof-of-concept results of its read-through platform in Spinal Muscular Atrophy.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 63%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>BioBlast Pharma Ltd. </U><BR>
        (Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
        By <U>/s/ Colin Foster</U></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Colin Foster</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 22, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v413718_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BioBlast Announces Positive Preclinical
Proof-Of-Concept Results Of Its Novel Read-through Platform in Spinal Muscular Atrophy (SMA)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TEL AVIV, Israel, June 22, 2015</B> &ndash; BioBlast Pharma
Ltd. (NasdaqGM: ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today positive preclinical <I>in
vitro</I> and <I>in vivo</I> proof-of-concept study results for its Read-through drug candidate (BBrm02) for Spinal Muscular Atrophy
(SMA). BBrm02 is a proprietary, intrathecal formulation of azithromycin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a series of cell and mouse studies BBrm02 was effective in
creating high levels of full length SMN2 protein (Survival Motor Neuron 2) in the central nervous system resulting in a high degree
of cellular and disease phenotypic rescues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant levels of full length SMN2 protein were detected
following treatment with BBrm02 in several different patient cell lines representing different stages of disease severity. This
SMN2 protein was tested for biological activity and was found to be highly functional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In two different mouse models of Spinal Muscular Atrophy, BBrm02
was effective in preventing weight loss, increasing animal survival, and in normalizing a range of neurological functions, including,
among others, the ability of the mouse to return to four feet from a supine position (&ldquo;time-to-right&rdquo; test) and to
walk on a narrow tube (&ldquo;tube-test&rdquo;), both of which measure equilibrium and muscle strength.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Colin Foster, BioBlast&rsquo;s President and CEO commented:
&ldquo;We are excited to share this comprehensive proof of concept as it establishes the efficacy of our lead drug candidate in
our Read-through Platform for Spinal Muscular Atrophy. Importantly, given that BBrm02 is a repurposed drug (azithromycin), we believe
there is a reasonable possibility for a short developmental process. We plan to start a Phase 2a study with BBrm02 at year-end,
2015.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Foster also noted that there are no drugs approved today
for SMA, which is an orphan disease with approximately 30,000 patients in the U.S. and an equal number in Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About BBrm &ndash; And Read-through Platform </I>&nbsp;
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BBrm is BioBlast&rsquo;s family of small molecule non-glycoside,
repurposed drugs for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense
mutation (stop codon). The platform enables the read-through (deactivation) of the genetic defects that stop synthesis of proteins
called stop codons. Deactivation of a disease-causing nonsense mutation can alleviate the symptoms of the corresponding genetic
disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>BBrm02 For The Treatment Of Spinal Muscular Atrophy (SMA)
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With our BBrm platform, BioBlast has developed a novel therapeutic
candidate for SMA. SMA is the leading genetic cause of infant mortality and is caused by the loss of a functional Survival Motor
Neuron 1 protein (SMN1). The disease is manifested by loss of muscle mass and mobility as well as severe compromises related to
vital functions such as respiration. Another protein called SMN2 (Survival Motor Neuron 2) is a nearly identical copy of SMN1,
differentiated only by a silent, single-nucleotide mutation within the DNA. SMN2 partially compensates for the dysfunction of SMN1,
however, the small amount of the functional protein that is produced from the SMN2 gene is not able to fully compensate for the
loss of SMN1. Prior independent studies proposed that read-through agents, such as aminoglycosides, could induce the read-through
of the stop codon located in the SMN2 gene, thus elongating the SMN2 and creating a full length functional protein that can compensate
for the non-functioning SMN1, thereby alleviating the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About BioBlast</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioBlast Pharma is a clinical-stage biotechnology company committed
to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has a diverse
portfolio of product candidates with the potential to address unmet medical needs for incurable genetic orphan diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The BioBlast platforms are based on deep understanding of the
disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.
For more information please visit the Company's website, www.bioblast-pharma.com, the content of which is not incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within
the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, we are using forward looking statements when we discuss the possibility for a short development process
for BBrm02 and our plan to start a Phase 2a study with BBrm02 at the end of 2015, or that our platforms potentially offer solutions
for several diseases that share the same biological pathology. In addition, historic results of scientific research and clinical
and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions
or that historic results would not be interpreted differently in light of additional research and clinical and preclinical trials
results. Because such statements deal with future events and are based on BioBlast Pharma Ltd.'s current expectations, they are
subject to various risks and uncertainties and actual results, performance or achievements of BioBlast Pharma could differ materially
from those described in or implied by the statements in this press release, including those discussed under the heading &quot;Risk
Factors&quot; in Bio Blast Pharma's prospectus dated July 30, 2014 filed with the Securities and Exchange Commission (&quot;SEC&quot;)
and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation
to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information,
future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Investor Contact</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andrew McDonald</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Founding Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>Andrew@LifeSciAdvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">646-597-6987</P>



<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``U`/@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BHKBXAM
M('GGD6.-!EF8]*X#4/&5[JM\;+26^S0<EYR/FVCJ1Z4FU%7>PTFW9'H990<$
M@'ZTI.!D]*\L:^EB?='++(>\DS;F)]?:IK_Q;?6'AJ=)I<RS_NX&)^;GJ?H*
M\[#YKA\15]E3NWZ:';5R^M2I>UG9+UU,[QMXTN+_`%"33M/F,=G$=KLG_+0]
M_P`*RO#>MW>AWJ2PR$PEOWD6>&%8-O:74[9B@E<]20IJY&&C;9(K*PZAABO2
M.$^@+:>.ZMHYXCE)%#*?:I:YWP1<FY\,0$G/EL8_RKHJ`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/+/'7B-KO47
MTV%\6]NV'P?O-6!H%T@U%XF(#31,B$]V]*PKN2X6\F6X!$X;YP?6J_F,&#!B
M"#D$=JSJTU4@X/9JQ4)N$E)=#UG1/#PU2TEF:;RY%;:H*[@"/45H_P#"!63R
M?:+B9KBXQC=*N5`]`O:L#P'XQMGN#97\BQ3R`!7)PLA_H:],[9KCP.!AAZ/)
M;7JUU^9U8K%2K5.>^G1=CA=;T.73+02I?%T4@>60!CZ5S.I(+_39GDYFMT,B
MR=]HZK6WXCU**X\7MIZR;A):_)SP7["JVE:+<ZL'B52L+GRY7/&%[X]Z\JK0
MG1S*FZ%^66^K:\^YZ$*L:N!G[:UX^27H=5X%MV@\*6I88\W,@^AKD_$?B'Q!
M>>.&T/0[M8@%"X/`#=R37I<44=K:I%&H6.-,*!Z"O%-*TJ\\6>+]8N[.^:R9
M9&<RK[]J^E/#.B\.^*O$%IXQ7P_K,D5SN.TM'SM/KGTK7$FJ77Q&(@UN$V,2
MX>S63GCKE?7WKE/A_*FG^,=1L[M$N+E$=OM9.2NWKS[U6\)WCQW'B?Q&H)E@
MB;83_>8\?RH`]7U#Q)HVE3"&^U*W@D_NNW-6H]0MKC3VO+>=)8-A8.IR*\E\
M)>'=/UKP]JFO:U(TTA+_`#,_W2!U_E5?P??36?@KQ.QD80JH$.3QN.1Q0!8T
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MB0\G/.<?G5GPA<>'-2T?4MNF_9;J*U*7`5OOKCD@T`:VG?$6&_\`%DVG,(8;
M"/<$N&?/F'MCZUVEY<?9[&:<'[B%@:\C^&GAFQUA[N\O8BZP2CR,-C!YZ_I7
MI?B:;R-#E`XWD)6&*J>RH3GV3-:$/:58Q[M&';7FO7EI+>PW"^5&3D'O5Q==
MENO#5S*YV7"?)N7CKWJA86&M3Z6MO`R1VLOS9/!.:DUJR32=$@L@VZ263<S>
MI%?,4ZF)A1=6\N7E=^9Z-O:WWGMRA1E45/2_-I;HEO<T=`U."#3$%[>KYTC$
M@.W..U="74)O+#;C.<\5PFK:7!I^E69P?M,IRQ)JSJ\\[QZ?I*N5W1J7YZYZ
M5V8?,:N&INE5CK%1MKJV]D_,YZN#A6FITY?$W?T78Z4ZWI@?8;V+=G&,U8DO
M;:(H))T4ORN3UKB=:TZUM+RTLK8?O.-[$Y))J?7XFN==M;&(X(15!]*IYKB(
M*:E!-Q<5I?=]/D2L#2DX\LG9IO7LCJQJ=D5D87,9$9`<YZ&FOJVGQE`UW$"X
MRO/6N;UZPM])TA+6#<6FD!8D]2*HZMID.GZ=8X!^T2\L2:=?,\52<DX1O%)O
M5]7L%+!4*G*U)^\VEMTZG:2:G8Q3"&2ZB60]%S5EY$C0N[!5'))-<'K.F0Z?
M!8*NXW$G,C$]>E7-9DEO=5M-)60K&`H8YZDCO5?VK5ASJI!<RY4DGUET?ZD_
M4(2Y7"6CO=OLNIT8UO3"^W[;%NZ8S17):AI]JFO6UA:K\O"L<YR:**>/QU24
MHQA%\KL]6$\+AH*+<FKJ_0W=8\&:+KD_GW5N1,>KQMM)^OK6=#\-?#T/S&*9
MV'=I"1^5=A17NGEGDEW:6]K<R6QLK4HC?*PCP2/K6]!XIE@TDVD<;F7&U'=]
MQ`^M1>,;"XTNZ;44MVN+"0YD"_>B;U'M[5RDGB&RCC+6<,LLO\)F&`I]?>OG
M:N%S2-5QI3O!]6]E_78]J&(P$J:E.%I+LMS/\33N-;C*.5F@B521U#"O4?`G
MB./6])\EU1+NWXD51@-Z-7C,_G3S/-*Q:1SN9CW-=#X`N9;7Q?:JF<39C<>Q
M[U[U.FH0C%=%8\B<W.3EW=SVRYC>:VEC1]CNI4-Z5YM!\*[VT,OV;Q!-")3\
M_EKC=]:].HK0@X_1O`-IH>G7D=O<-)>W,9C-S(.0#Z"G^'?`T&C:+?:=<SFY
M2\R)#MV\5UM%`'F`^%E]%YMI!KTL>G2MEXP.H]Q70WO@2V?PB-!L)S;J9%D>
M4C)<CKGZUUU%`'F:?"NZ,*VLOB"<V@.?*"\?E6SJ?P_MKCPQ#H=A<&VA642N
MQ&XNWO79T4`<;K/@&'5/#-AI:W!CFL5Q'+C.?7(]ZQ)/A3-<VT/VG6I9+A"!
MEER%4=`*]-HH`XK7?"&L7UW%/IVO36:+"L)B3@<=ZDT'P#;:-I=_;O=/-<7R
M%))<8P/85V-%`'#^$/`MUX8U66X;4FEMRI41`8!SW/O72ZUI3:M`D0F\M5;)
MXSFM.BLZU*%:#IS5TRZ=25.2G'=$-K`+:UB@4Y"*%S6;K&B'5;B!S/L2+^'&
M<UL45%7#TZM/V4U[NGX%0K3A/VD7J8VKZ&=4EMR9]B1?PXZTS6/#XU&6.>*;
MRI4`7..H%;E%95,!AZG-S1^*U_EL7#%U8<O*]KV^>YS<7A8QWL-RUVSNC!G+
M#.XU<70S_;IU)YL\Y"8Z5L45,,NPT-(QZWW>Z*EC*TMWTM\C(UC13JT\#F?8
ML7\.,YINIZ&=1N[>4S;4BQ\N.M;-%7/`T)N3DOBLW\MB8XJK&R3VO;Y[F/J&
MAF_U&"Y:;"18^3'6H=5\.F^O5N[><PR8`/'IWK>HJ:F7X>HI*4?B=WZH<,76
MA:SV5CGK7PP+74HKL73.4.6W#EC170T5KA\+2PZ<:2LGJ9U:\ZS3F[V"BBBN
M@R&NBR(R.H96&"",@UQ>M^`-+D66[M6>U(&XH@RI_P`***`//+FQ2*Z$`8D9
MQG%>C^#?"5EIJKJF]IKB1<*6&`@]J**`.RHHHH`****`"BBB@`HHHH`****`
C"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
